A Fixed-Duration Immunochemotherapy Approach Combined with Ibrutinib in CLL Produces Deep and Sustained MRD Responses: 5.5-Year Results from the Icll-07 Filo Trial Anne-Sophie Michallet , Remi Letestu , Magali Le Garff-Tavernier , Carmen Aanaei , Michel Ticchioni , Marie-Sarah Dilhuydy , Stephane Morisset , Valerie Rouille , Beatrice Mahe , Kamel Laribi , Bruno Villemagne , Emmanuelle Ferrant , Olivier Tournilhac , Alain Delmer , Christelle Portois , Lysiane Molina , Veronique Leblond , Cecile Tomowiak , Sophie de Guibert , Frederique Orsini , Anne Banos , Philippe Carassou , Guillaume Cartron , Luc Mathieu Fornecker , Loic Ysebaert , Caroline Dartigeas , Margot Truchan , Jean-Pierre Vilque , Therese Aurran Schleinitz , Cymbalista Florence , Stephane Lepretre , Vincent Levy , Florence Nguyen Khac , Pierre Feugier Blood（2022）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
